omeprazole has been researched along with Shock, Septic in 3 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Shock, Septic: Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Especially patients with severe sepsis or septic shock are prone to develop lesions of the upper gastrointestinal tract with consecutive bleeding." | 1.35 | [Stress ulcer prophylaxis in septic patients. Evidence-based overview]. ( Elke, G; Schädler, D; Scholz, J; Weiler, N; Zick, G, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balza, E | 1 |
| Piccioli, P | 1 |
| Carta, S | 1 |
| Lavieri, R | 1 |
| Gattorno, M | 1 |
| Semino, C | 1 |
| Castellani, P | 1 |
| Rubartelli, A | 1 |
| Elke, G | 1 |
| Schädler, D | 1 |
| Zick, G | 1 |
| Scholz, J | 1 |
| Weiler, N | 1 |
| Mertens, PR | 1 |
| Schönfelder, T | 1 |
| Handt, S | 1 |
| Kierdorf, H | 1 |
| Marschall, H | 1 |
| Busch, N | 1 |
| Heintz, B | 1 |
| Sieberth, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proton Pump Inhibitors (PPI) as a New Strategy for Therapy in Sepsis: Clinical Trial to Reduce Severity of Organ Failure and in Vitro Experiments to Search Specific Hallmarks in Monocytes From Septic Patients and to Characterize the Mechanism of Action of[NCT03452865] | Phase 3 | 300 participants (Anticipated) | Interventional | 2020-01-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for omeprazole and Shock, Septic
| Article | Year |
|---|---|
Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance.
Topics: Animals; Cryopyrin-Associated Periodic Syndromes; Esomeprazole; Gene Expression Regulation; Humans; | 2016 |
[Stress ulcer prophylaxis in septic patients. Evidence-based overview].
Topics: Anti-Ulcer Agents; Cimetidine; Duodenal Ulcer; Evidence-Based Medicine; Gastric Acid; Gastrointestin | 2008 |
Long-term extracorporeal bilirubin elimination: A case report on cascade resin plasmaperfusion.
Topics: Acute Kidney Injury; Bile Acids and Salts; Charcoal; Chemical and Drug Induced Liver Injury; Cholest | 1998 |